1. Drug Delivery Partnering Terms and Agreements
Report Details:
Published:November 2012
No. of Pages: 1069
Price: Single User License – US$2995
The Drug Delivery Partnering Terms and Agreements report provides comprehensive
understanding and unprecedented access to the drug delivery partnering deals and agreements
entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter drug
delivery partnering deals. The majority of deals are discovery or development stage whereby the
licensee obtains a right or an option right to license the licensors drug delivery technology. These
deals tend to be multicomponent, starting with collaborative R&D, and commercialization of
outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical
insight into the negotiation process in terms of what you can expect to achieve during the
negotiation of terms. Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are triggered – contract documents
provide this insight where press releases do not.
This report contains over 2,000 links to online copies of actual drug delivery deals and contract
documents as submitted to the Securities Exchange Commission by companies and their
partners. Contract documents provide the answers to numerous questions about a prospective
partner’s flexibility on a wide range of important issues, many of which will have a significant
impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of drug delivery dealmaking and business
activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview
of the trends in drug delivery dealmaking since 2007, including details of average headline,
upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading drug delivery deals since 2007. Deals are listed by
headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma
companies. Where the deal has an agreement contract published at the SEC a link provides
online access to the contract.

2. Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief
summary followed by a comprehensive listing of drug delivery deals as well as contract documents
available in the public domain. Where available, each deal title links via Weblink to an online
version of the actual contract document, providing easy access to each contract document on
demand.
Chapter 5 provides a comprehensive and detailed review of drug delivery partnering deals signed
and announced since 2007, where a contract document is available in the public domain. The
chapter is organized by company A-Z, stage of development at signing, deal type (collaborative
R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to
an online version of the deal record and the contract document, providing easy access to each
contract document on demand.
Chapter 6 provides a comprehensive and detailed review of drug delivery partnering deals
organized by specific drug delivery technology type. Each deal title links via Weblink to an online
version of the deal record and where available, the contract document, providing easy access to
each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in
drug delivery partnering and dealmaking since 2007.
In addition, a comprehensive appendix is provided organized by drug delivery partnering company
A-Z, deal type definitions and drug delivery partnering agreements example. Each deal title links
via Weblink to an online version of the deal record and where available, the contract document,
providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about
partnering in the research, development and commercialization of drug delivery technologies and
products.
Drug Delivery Partnering Terms and Agreements is intended to provide the reader with an in-
depth understanding and access to drug delivery trends and structure of deals entered into by
leading companies worldwide.
This research includes:
• Trends in drug delivery dealmaking in the biopharma industry since 2007
• Analysis of drug delivery deal structure
• Access to headline, upfront, milestone and royalty data
• Case studies of real-life drug delivery deals
• Access to over 2,000 drug delivery contract documents

3. • The leading drug delivery deals by value since 2007
• Most active drug delivery dealmakers since 2007
• The leading drug delivery partnering resources
In Drug Delivery Partnering Terms and Agreements, the available contracts are listed by:
• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the
contract document, providing easy access to each contract document on demand.
Key Benefits of this report:
• In-depth understanding of drug delivery deal trends since 2007
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of drug delivery agreements with numerous real life case studies
• Comprehensive access to over 2,000 actual drug delivery contracts entered into by the world’s
biopharma companies
• Detailed access to actual drug delivery contracts enter into by the leading fifty bigpharma
companies
• Insight into the terms included in a drug delivery agreement, together with real world clause
examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner
companies
Get your copy of this report @
http://www.reportsnreports.com/reports/206436-drug-delivery-partnering-terms-and-agreements.html
Major points covered in Table of Contents of this report include
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in drug delivery dealmaking
2.1. Introduction
2.2. Drug delivery partnering over the years
2.3. Bigpharma drug delivery dealmaking activity

4. 2.4. Drug delivery partnering by deal type
2.5. Drug delivery partnering by disease type
2.6. Partnering by drug delivery technology type
2.7. Average deal terms for drug delivery partnering
2.7.1 Drug delivery headline values
2.7.2 Drug delivery upfront payments
2.7.3 Drug delivery milestone payments
2.7.4 Drug delivery royalty rates
2.8. The anatomy of drug delivery partnering
2.9. Drug delivery or specialty pharma?
2.9.1. Is specialty pharma the only way for drug delivery?
2.9.2. Best practice for optimizing drug delivery program development
2.9.3. The anatomy of a drug delivery deal
2.9.3.a. Case study 1: Alpharma – Durect
2.3.3.b. Case study 2: Bayer – MDRNA
2.3.3.c. Case study 3: Aradigm – Lung Rx
Chapter 3 – Leading drug delivery deals
3.1. Introduction
3.2. Top drug delivery deals by value
Chapter 4 – Bigpharma drug delivery deals

5. 4.1. Introduction
4.2. How to use bigpharma drug delivery partnering deals
4.3. Bigpharma drug delivery partnering company profiles
Abbott
Actavis
Actelion
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai

6. Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche

7. Sanofi
Servier
Shionogi
Shire
Takeda
Teva
Warner Chilcott
Watson
Chapter 5 – Drug delivery partnering contracts directory
5.1. Introduction
5.2. Company A-Z
5.3. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA

8. Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Royalty financing
Settlement
Spin out
Sub-license
Supply
Technology transfer

9. Termination
Warranty
5.4. By stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
5.5. By therapy area
Anaesthetics
Cardiovascular
Central Nervous System
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Gynaecology
Hematology

10. Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Pediatrics
Respiratory
Chapter 6 – Drug delivery dealmaking by technology type
6.1. Introduction
6.2. Deals by drug delivery type
Drug delivery
Bioavailability
Implantable
Oral delivery
Delayed release
Rapid release
Parenteral
Infusion
Injectable

11. Pro-drug
Targeted
Topical
Transdermal
Transmucosal
Buccal
Inhaled
Nasal
Ocular
Rectal
Sublingual
Urogenital
About Wildwood Ventures
Current Partnering
Current Agreements
Current Reports
Recent titles from CurrentPartnering
Appendices
Introduction

12. Appendix 1 – Directory of drug delivery deals by company A-Z 2007-2012
Appendix 2 – Directory of drug delivery deals by stage of development 2007-2012
Appendix 3 – Directory of drug delivery deals by deal type 2007-2012
Appendix 4 – Directory of drug delivery deals by therapy area 2007-2012
Appendix 5 – Drug delivery partnering resource center Online drug delivery partnering Drug
delivery partnering events Further reading on drug delivery dealmaking
Table of Figures
Figure 1: Drug delivery partnering since 2007
Figure 2: Bigpharma – top 50 – drug delivery deals 2007 to 2012
Figure 3: Bigpharma drug delivery deal frequency – 2007 to 2012
Figure 4: Drug delivery partnering by deal type since 2007
Figure 5: Drug delivery partnering by disease type since 2007
Figure 6: Drug delivery partnering by technology type since 2007
Figure 7: Drug delivery deals with a headline value
Figure 8: Drug delivery deal headline value distribution, US$million – discovery stage
Figure 9: Drug delivery deal headline value distribution, US$million – preclinical stage
Figure 10: Drug delivery deal headline value distribution, US$million – phase I stage
Figure 11: Drug delivery deal headline value distribution, US$million – phase II stage
Figure 12: Drug delivery deal headline value distribution, US$million – phase III stage
Figure 13: Drug delivery deal headline value distribution, US$million – regulatory stage

13. Figure 14: Drug delivery deal headline value distribution, US$million – marketed stage
Figure 15: Drug delivery deal headline value distribution, US$million – formulation stage
Figure 16: Summary median headline value by stage of development, 2007-2012
Figure 17: Drug delivery deals with upfront payment values
Figure 18: Drug delivery deal upfront payment distribution, US$million – discovery stage
Figure 19: Drug delivery deal upfront payment distribution, US$million – preclinical stage
Figure 20: Drug delivery deal upfront payment distribution, US$million – phase I stage
Figure 21: Drug delivery deal upfront payment distribution, US$million – phase II stage
Figure 22: Drug delivery deal upfront payment distribution, US$million – phase III stage
Figure 23: Drug delivery deal upfront payment distribution, US$million – regulatory stage
Figure 24: Drug delivery deal upfront payment distribution, US$million – marketed stage
Figure 25: Drug delivery deal upfront payment distribution, US$million – formulation stage
Figure 26: Summary median upfront payments by stage of development, 2007-2012
Figure 27: Drug delivery deals with milestone payments
Figure 28: Drug delivery deal milestone distribution, US$million – discovery stage
Figure 29: Drug delivery deal milestone distribution, US$million – preclinical stage
Figure 30: Drug delivery deal milestone distribution, US$million – phase I stage
Figure 31: Drug delivery deal milestone distribution, US$million – phase II stage
Figure 32: Drug delivery deal milestone distribution, US$million – phase III stage
Figure 33: Drug delivery deal milestone distribution, US$million – regulatory stage
Figure 34: Drug delivery deal milestone distribution, US$million – marketed stage

14. Figure 35: Drug delivery deal milestone distribution, US$million – formulation stage
Figure 36: Drug delivery deals with royalty rates, %
Figure 37: Drug delivery deal royalty rate distribution, US$million – discovery stage
Figure 38: Drug delivery deal royalty rate distribution, US$million – preclinical stage
Figure 39: Drug delivery deal royalty rate distribution, US$million – phase I stage
Figure 40: Drug delivery deal royalty rate distribution, US$million – phase II stage
Figure 41: Drug delivery deal royalty rate distribution, US$million – phase III stage
Figure 42: Drug delivery deal royalty rate distribution, US$million – regulatory stage
Figure 43: Drug delivery deal royalty rate distribution, US$million – marketed stage
Figure 44: Drug delivery deal royalty rate distribution, US$million – formulation stage
Figure 45: Summary median royalty rate by stage of development, 2007-2012
Figure 46: Components of the typical drug delivery deal structure
Figure 47: Best practice for drug delivery program development
Figure 48: Top drug delivery deals by value since 2007
Contact: sales@reportsandreports.com for more information.